Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2020; 74(2): 130–134. doi:10.14735/amgh2020130.

Recommendations of the Slovak IBD Working Group on SGS for the Treatment of Biosimilar Anti-TNF Biologics in Adult and Pediatric Patients

Barbora Kadlečková1,2, Igor Šturdík3,4, Peter Lietava5,6, Laura Gombošová7, Iveta Čierna8, Tibor Hlavatý4, Martin Huorka9

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Fiorino G, Caprioli F, Daperno M et al. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis 2019; 51(5): 632–639. doi: 10.1016/j.dld.2019.02.004.
2. Weise M, Kurki P, Wolff-Holz E et al. Biosimilars: the science of extrapolation. Blood 2014; 124(22): 3191–3196. doi: 10.1182/blood-2014-06-583617.
3. Brown BB. A methodology used for the elicitation of opinions of experts. Delphi Process 1968; document no: P-3925: 15.
4. Calvet X, Panés J, Alfaro N et al. Delphi consensus statement: quality indicators for inflammatory bowel disease comprehensive care units. J Crohns Colitis 2014; 8(3): 240–251. doi: 10.1016/j.crohns.2013.10.010.
5. CEMB. OCEBM Levels of Evidence. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine 2011. [online]. Available from: http://www.cebm.net/index.aspx?o=5653.
6. Howick J et al. The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document). [online]. Available from: http://www.cebm.net/index.aspx?o=5653.
7. Farkas K, Rutka M, Bálint A et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center. Expert Opin Biol Ther 2015; 15(9): 1257–1262. doi: 10.1517/14712598.2015.1064893.
8. Kang YS, Moon HH, Lee SE et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2015; 60(4): 951–956. doi: 10.1007/s10620-014-3392-z.
9. Park SH, Kim YH, Lee JH et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 2015; 9 (Suppl 1): 35–44. doi: 10.1586/17474124.2015.1091309.
10. Smits LJ, Derikx LA, de Jong DJ et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis 2016; 10(11): 1287–1293. doi: 10.1093/ecco-jcc/jjw087.
11. Gecse KB, Lovász BD, Farkas K et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis 2016; 10(2): 133–140. doi: 10.1093/ecco-jcc/jjv220.
12. Jørgensen KK, Olsen IC, Goll GL et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389(10086): 2304–2316.
doi: 10.1016/S0140-6736(17)30068-5.
13. Fiorino G, Manetti N, Armuzzi A et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis 2017; 23(2): 233–243. doi: 10.1097/MIB.0000000000000995.
14. Armuzzi A, Fiorino G, Variola A et al. The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy. Inflamm Bowel Dis 2019; 25(3): 568–579. doi: 10.1093/ibd/izy264.
15. Meyer A, Rudant J, Drouin J et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study. Ann Intern Med 2019; 170(2): 99–107. doi: 10.7326/M18-1512.
16. Gonczi L, Gecse KB, Vegh Z et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflamm Bowel Dis 2017; 23(11): 1908–1915. doi: 10.1097/MIB.0000000000001237.
17. Jøergensen KK, Goll GL, Sexton J et al. Long-term efficacy and safety of CT-P13 after switching from originator infliximab: exploratory subgroup analyses in IBD in the NOR-SWITCH extension trial. Gastroenterology 2018; 154(6) (Suppl 1): S168. doi: 10.1016/S0016-5085(18)30973-9.
18. Smits LJ, van Esch AAJ, Derikx LAA et al. Drug survival and immunogenicity after switching from remicade to biosimilar CT-P13 in inflammatory bowel disease patients: two-year follow-up of a prospective observational cohort study. Inflamm Bowel Dis 2019; 25(1): 172–179. doi: 10.1093/ibd/izy227.
19. Buer LC, Moum BA, Cvancarova M et al. Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis 2017; 11(3): 297–304. doi: 10.1093/ecco-jcc/jjw166.
20. Razanskaite V, Bettey M, Downey L et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis 2017; 11(6): 690–696. doi: 10.1093/ecco-jcc/jjw216.
21. Kim YH, Ye BD, Pesegova M et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab (INX) in patients with active Crohn’s disease: 1-year maintenance and switching results. UEG Journal 2017; 5 (Suppl 1).
22. Komaki Y, Yamada A, Komaki F et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther 2017; 45(8): 1043–1057. doi: 10.1111/apt.13990.
23. Kurti Z, Gonczi L, Lakatos PL. Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opin Biol Ther 2018; 18(6): 633–640. doi: 10.1080/14712598.2018.1469620.
24. Bergqvist V, Kadivar M, Molin D et al. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Ther Adv Gastroenterol 2018; 11: 1–13. doi: 10.1177/1756284818801244.
25. Fiorino G, Gilardi D, Correale C et al. Biosimilars of adalimumab: the upcoming challenge in IBD. Expert Opin Biol Ther 2019; 19(10): 1023–1030. doi: 10.1080/14712598.2019.1564033.
26. Ilias A, Szanto, Gonczi L et al. Outcomes of patients with inflammatory bowel diseases switched from maintenance therapy with a biosimilar to Remicade. Clin Gastroenterol Hepatol 2019; 17(12): 2506–2513. doi: 10.1016/j.cgh.2018.12.036.
27. Strik A, Van de Vrie W, Bloemsaat-Minekus JPJ et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol 2018; 3(6): 404–412. doi: 10.1016/S2468-1253(18)30082-7.
28. Kolar M, Duricova D, Bortlik M et al. Biosimilar infliximab in anti-TNF naïve IBD patients – 1 year clinical follow up. Gastroent Hepatol 2016; 70(6): 514–522. doi: 10.14735/amgh2016514.
29. Kolar M, Bortlik M, Duricova D et al. Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab. Gastroent Hepatol 2018; 72(1): 20–26. doi:10.14735/amgh201820.
30. Duricova D, Dvorakova E, Kozeluhova J et al. Anti-TNF-α exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of life. J Crohns Colitis 2018; 12 (Suppl 1)? S482–S483. P734. doi: 10.1093/ecco-jcc/jjx180.861.
31. Shihab Z, Yeomans ND, De Cruz P et al. Anti-tumour necrosis factor α therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis. J Crohns Colitis 2016; 10(8): 979–988. doi: 10.1093/ecco-jcc/jjv234.
32. de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenterol 2016; 111(9): 1305–1312. doi: 10.1038/ajg.2016.254.
33. Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 2018; 11: 215–226. doi: 10.2147/JIR.S165330.
34. Ridder L, Assa A, Bronsky J et al. Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr 2019; 68(1): 144–153. doi: 10.1097/MPG.0000000000002141.

Kreditovaný autodidaktický test